- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03296540
CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI (CompareCrush)
COMPARison of Pre-hospital CRUSHed vs. Uncrushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Interventions
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The study is a two-centre, randomized, 1:1 trial comparing prehospital prasugrel initiation therapy between crushed vs. uncrushed prasugrel tablets on efficacy and safety as well as pharmacodynamics in STEMI patients.
Patients with STEMI planned for primary PCI will be screened and, if inclusion criteria are met, included at first medical contact (paramedics). After enrolment, patients will be randomly assigned (1:1) to receive 60mg prasugrel loading dose by ingesting integral or crushed tablets.
The follow-up duration is 12 months, i.e. clinical outcomes will be analysed in-hospital, at 30 days, and 12 months
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Rotterdam, Nederland, 3015 CE
- Erasmus Medical Center
-
Rotterdam, Nederland, 3079 DZ
- Maasstadziekenhuis
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Consecutive patients with STEMI planned for primary PCI:
- Deferred written informed consent within 4 hours after prasugrel loading dose
- Adult men and women aged at least 18 years
- Symptoms of acute MI of more than 30 min but less than 6 hours
- New persistent ST-segment elevation ≥ 1 mm in two or more contiguous ECG leads
Exclusion Criteria:
- Contraindication to prasugrel (e.g., hypersensitivity, active bleeding, history of previous intracranial bleed, history of any CVA including TIA, moderate to severe hepatic impairment, GI bleed within the past 6 months, major surgery within past 4 weeks)
- Patient who has received loading dose of clopidogrel or ticagrelor for the index event or are on chronic treatment of ticagrelor, or prasugrel. However, patients on maintenance dose clopidogrel for at least 7 days are included in the study (see appendix A).
- Oral anticoagulation therapy that cannot be stopped (i.e. patients requiring chronic therapy)
- Planned fibrinolytic treatment
- Patient requiring dialysis
- Known, clinically important thrombocytopenia
- Known clinically important anaemia
- Known pregnancy or lactation
- Need for a concomitant systemic therapy with strong inhibitors or strong inducers of CYP3A
- Condition which may either put the patient at risk or influence the result of the study (e.g., cardiogenic shock with severe hemodynamic instability, active cancer, risk for non-compliance, risk for being lost to follow up)
- Patient unable to swallow oral medication (i.e. intubated patients)
- Patient who have not received prasugrel loading dose in the ambulance
- Patient who vomited after randomization / receiving the loading dose prasugrel
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Uncrushed
6 Integral tablets Prasugrel as loading dose
|
loading dose of 6 integral tablets of 10mg Prasugrel
Andre navn:
|
Eksperimentell: Crushed
6 Crushed tablets Prasugrel as loading dose
|
loading dose of 6 crushed tablets 10mg Prasugrel
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Co-primary endpoint is the percentage of patients reaching TIMI flow grade 3 of MI culprit vessel at initial angiography or a ≥70% ST-segment resolution directly post-PCI
Tidsramme: directly post PCI
|
To assess the efficacy of crushed vs. integral tablets of prasugrel loading dose treatment by comparing the percentage of patients reaching the co-primary endpoint of TIMI flow grade 3 of MI culprit vessel at initial angiography or a ≥70% ST-segment elevation resolution directly post-PCI.
|
directly post PCI
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Composite of death, MI, stroke, urgent revascularization and acute stent thrombosis in hospital, at 30 days and 12 months
Tidsramme: upto 72 hours after randomisation, at 30 days and 12 months.
|
Percentage of patients in the following: composite of death, MI, stroke, urgent revascularization and acute stent thrombosis during inhospital stay, 30 days and 12 months of study
|
upto 72 hours after randomisation, at 30 days and 12 months.
|
Composite of death, MI, urgent revascularization during inhospital, at 30 days and 12 months of study
Tidsramme: 30 days and 12 months
|
Percentage of patients in the following: composite of death, MI, or urgent revascularization during inhospital, 30 days and 12 months of study
|
30 days and 12 months
|
Individual endpoints during inhospital, at 30 days and 12 months of study
Tidsramme: upto 72 hours after randomisation, at 30 days and 12 months.
|
Percentage of patients presenting with any of the individual endpoints during inhospital, 30 days and 12 months of study
|
upto 72 hours after randomisation, at 30 days and 12 months.
|
Thrombotic bail-out with GPIIb/IIIa inhibitors at initial PCI
Tidsramme: directly post PCI
|
Percentage of patients receiving thrombotic bail-out with GPIIb/IIIa inhibitors at initial PCI
|
directly post PCI
|
Complete (≥ 70%) ST-segment elevation resolution pre-PCI and 60 min post-PCI
Tidsramme: pre-PCI and 60 min post-PCI
|
Complete (≥ 70%) ST-segment elevation resolution pre-PCI and 60 min post-PCI
|
pre-PCI and 60 min post-PCI
|
Corrected TIMI frame count (cTFC) at angiography, pre and post PCI.
Tidsramme: pre PCI, directly post PCI
|
Corrected TIMI frame count (cTFC) at angiography, pre and post PCI
|
pre PCI, directly post PCI
|
TIMI myocardial perfusion grade (TMPG) at angiography, pre and post PCI.
Tidsramme: pre PCI, directly post PCI
|
TIMI myocardial perfusion grade (TMPG) at angiography, pre and post PCI.
|
pre PCI, directly post PCI
|
Time-relationship (from symptom onset to 1st dose intake) on each co-primary
Tidsramme: directly post-PCI
|
Time from symptom onset to 1st dose intake correlated to TIMI flow grade 3 of MI culprit vessel at initial angiography and on ≥70% ST-segment elevation resolution directly post-PCI
|
directly post-PCI
|
Time-relationship (from 1st dose intake to ECG/ angiography) on each co-primary
Tidsramme: directly post-PCI
|
Time from first dose intake to ECG correlated to ≥70% ST-segment elevation resolution directly post-PCI and time from randomization to initial angiography correlated to TIMI flow grade 3 of MI culprit vessel
|
directly post-PCI
|
TIMI flow grade 3 at end of procedure.
Tidsramme: directly post PCI
|
TIMI flow grade 3 at end of procedure.
|
directly post PCI
|
Myocardial Blush at the start and end of the procedure
Tidsramme: pre PCI, directly post PCI
|
Myocardial Blush at the start and end of the procedure
|
pre PCI, directly post PCI
|
Maximum CK, and CK-MB levels
Tidsramme: upto 72 hours after randomisation
|
Maximum CK, and CK-MB levels
|
upto 72 hours after randomisation
|
Level of platelet inhibition at first medical contact, beginning and end of PCI procedure, as well as at 4 hours after prasugrel administration
Tidsramme: at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
Level of platelet inhibition at first medical contact, beginning and end of PCI procedure, as well as at 4 hours after prasugrel administration
|
at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
Platelet reactivity, at each time point as well as over time
Tidsramme: at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
PRU measurements at first medical contact, beginning and end of PCI, as well as 4hours after drug administration
|
at time of prasugrel administration, pre PCI, directly post PCI, 4 hours after prasugrel administration
|
Rates of HPR
Tidsramme: upto 72 hours after randomisation
|
Percentage of patients with PRU values over HPR threshold
|
upto 72 hours after randomisation
|
Exploratory analyses within each group to evaluate any differences in PD among patients receiving morphine
Tidsramme: upto 72 hours after randomisation
|
PD of each group among patients stratified for morphine treatment
|
upto 72 hours after randomisation
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: George Vlachojannis, MD, PhD, Maasstadziekenhuis
- Studieleder: Pieter C Smits, MD, PhD, Maasstadziekenhuis
- Studiestol: Nicolas van Mieghem, MD, PhD, Erasmus Medical Center
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Vlachojannis GJ, Wilschut JM, Vogel RF, Lemmert ME, Delewi R, Diletti R, van der Waarden NWPL, Nuis RJ, Paradies V, Alexopoulos D, Zijlstra F, Montalescot G, Angiolillo DJ, Krucoff MW, Van Mieghem NM, Smits PC. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Circulation. 2020 Dec 15;142(24):2316-2328. doi: 10.1161/CIRCULATIONAHA.120.051532. Epub 2020 Oct 14.
- Vlachojannis GJ, Vogel RF, Wilschut JM, Lemmert ME, Delewi R, Diletti R, van Vliet R, van der Waarden N, Nuis RJ, Paradies V, Alexopoulos D, Zijlstra F, Montalescot G, Angiolillo DJ, Krucoff MW, Van Mieghem NM, Smits PC. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. Am Heart J. 2020 Jun;224:10-16. doi: 10.1016/j.ahj.2020.03.005. Epub 2020 Mar 11.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2017-40
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Prasugrel (Integral tablets)
-
Fundació Institut de Recerca de l'Hospital de la...Tilbaketrukket
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.Fullført
-
The Queen Elizabeth HospitalFullført
-
Gyeongsang National University HospitalFullførtBlør | Akutt koronarsyndrom | BlodplatetrombeKorea, Republikken
-
University of MilanFullført
-
University of PatrasFullført
-
Medstar Health Research InstituteFullførtAkutt koronarsyndromForente stater
-
University of FloridaFullførtKoronararteriesykdomForente stater
-
VA Office of Research and DevelopmentFullført